Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

INCB018424 in Patients With Advanced Hematologic Malignancies

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Acute Lymphocytic Leukemia
Myelodysplastic Syndrome
Chronic Myelogenous Leukemia

Interventions: Drug: INCB018424

First Posted Date: 2008-05-07

Last Posted Date: 2025-06-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 51

Registration Number: NCT00674479

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I

Phase 1

Terminated

Conditions: Malignant Gliomas

Interventions: Drug: Irinotecan
Drug: Lenalidomide

First Posted Date: 2008-05-05

Last Posted Date: 2018-11-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT00671801

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Evaluation of Robot-Assisted Surgery in Gynecologic Oncology

Completed

Conditions: Gynecologic Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2008-05-05

Last Posted Date: 2020-12-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 588

Registration Number: NCT00671827

Locations: 🇺🇸
MD Anderson Banner Arizona, Gilbert, Arizona, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Leukemia
Acute Lymphoblastic Leukemia

Interventions: Drug: Rituximab
Drug: Cyclophosphamide (CTX)
Drug: Doxorubicin
Drug: Vincristine
Drug: Dexamethasone
Drug: Methotrexate (MTX)
Drug: Cytarabine
Drug: G-CSF
Drug: Mesna
Drug: Pegylated asparaginase
Drug: Pegfilgrastim
Drug: Solumedrol

First Posted Date: 2008-05-05

Last Posted Date: 2020-12-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 220

Registration Number: NCT00671658

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Hysteroscopic Lymphatic Mapping for Endometrial Cancer

Phase 2

Terminated

Conditions: Endometrial Cancer

Interventions: Procedure: Intraoperative Lymphatic Mapping

First Posted Date: 2008-05-05

Last Posted Date: 2016-05-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00671606

Locations: 🇺🇸
St. Luke's Episcopal Hospital, Houston, Texas, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

Phase 2

Completed

Conditions: Burkitt's Lymphoma
Burkitt'S-like Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Dexamethasone
Drug: G-CSF
Drug: Cytarabine
Drug: Methotrexate

First Posted Date: 2008-05-01

Last Posted Date: 2018-05-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 56

Registration Number: NCT00669877

Locations: 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation

Phase 3

Conditions: Prostate Cancer

Interventions: Radiation: Hypofractionated Intensity Modulated Radiotherapy
Radiation: Conventional Fractionated Intensity Modulated Radiotherapy

First Posted Date: 2008-04-28

Last Posted Date: 2021-01-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 225

Registration Number: NCT00667888

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Long Term Minor Sibling Donor Well-Being

Terminated

Conditions: Disorder Related to Bone Marrow Transplantation
Blood Stem Cell Transplant Failure
Disturbance of Emotions Specific to Childhood and Adolescence
Transmission, Blood, Recipient/Donor
Sibling

Interventions: Behavioral: Questionnaire

First Posted Date: 2008-04-28

Last Posted Date: 2012-04-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00667784

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: 2CdA
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2008-04-28

Last Posted Date: 2022-03-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT00667329

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal

Phase 3

Completed

Conditions: Smoking

Interventions: Other: Functional Magnetic Resonance Imaging (fMRI)

First Posted Date: 2008-04-23

Last Posted Date: 2012-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 64

Registration Number: NCT00664404

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy